Company: LIMN
Filing Date: 2025-06-02
Form Type: 8-K/A
Source: 0001104659-25-055078
Chunk: 8

Company: Liminatus Pharma, Inc.
Filing Date: 2025-06-02
Form: 8-K/A
Chunk 8
---
 as a public company. |

Business Combination

On November 30,
2022, we entered into a business combination agreement (the “Business Combination Agreement”), with Iris Acquisition Corp,
a Delaware publicly traded special purpose acquisition company (“Iris”), Iris Parent Holding Corp., a Delaware corporation
(“ParentCo”), Liminatus Pharma Merger Sub, Inc., a wholly-owned subsidiary of ParentCo (“Liminatus Merger Sub”),
and SPAC Merger Sub, Inc., a wholly-owned subsidiary of ParentCo (“SPAC Merger Sub” and together with Liminatus Merger
Sub, the “Merger Subs”).

On June 1,
2023, we entered into an amendment to the Business Combination Agreement to extend the Outside Date, as defined in the Business Combination
Agreement, to September 11, 2023.

On August 14,
2023, we entered into a second amendment to the Business Combination Agreement to extend the Outside Date, as defined in the Business
Combination Agreement, to March 9, 2024.

On March 9,
2024, we entered into a third amendment to the Business Combination Agreement to extend the Outside Date, as defined in the Business Combination
Agreement, to July 31, 2024.

On July 19,
2024, we entered into a fourth amendment to the Business Combination Agreement to extend the Outside Date, as defined in the Business
Combination Agreement, to September 3, 2024.

<div align='center'>5</div>

On August 16,
2024, we entered into a fifth amendment to the Business Combination Agreement to extend the Outside Date, as defined in the Business Combination
Agreement, to December 31, 2024.

On October 23,
2024, we entered into a sixth amendment to the Business Combination Agreement to, among other things, reduce the enterprise value associated
with the Company to $175 million.

OnDecember 26, 2024, we entered into a seventh amendment to the Business Combination Agreement to extend the Outside Date, as defined in the Business Combination Agreement, to June 30, 2025.

In consideration
of the Liminatus Merger, our securityholders will receive 17,500,000 newly issued shares of ParentCo’s common stock with an aggregate
equity value of $175.0 million.

Pursuant to the Business Combination Agreement, onApril 30, 2025, in sequential order: (a) Limin